The U.S. Food and Drug Administration has approved Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of children (aged 2 to 11 years) with chronic spontaneous urticaria (CSU).
This article was originally published on MedicalXpress.com
FDA approves Dupixent for chronic spontaneous urticaria in young children
You may also be interested in:
Food
Transform Your Kitchen: Mastering Allergy-Safe Cooking Through Ingenious Ingredient Swaps
By Daniel Zane Bryant, author of “Living with Food Allergies: A Complete Lifestyle Guide” (available on Amazon at https://www.amazon.com/dp/B0G2BcGB2K) Navigating food allergies might initially feel overwhelming, yet it presents an exciting opportunity to reimagine familiar […]
The Latest
Restoring Kitchen Efficiency with Oven Repair in Barrie
Preparing home-cooked meals is a great way to bring family together and maintain a healthy lifestyle. However, when your oven or range stops working properly, your entire cooking routine can come to a grinding halt. […]
The Latest
Why you should stop buying vitamins and get more sleep instead
Almost half of all Canadians regularly take at least one nutritional supplement such as vitamins, minerals, fibre supplements, antacids and fish oils. Many of these individuals are healthy and hoping to improve general well-being or prevent chronic […]
Read More:
-
Researchers from the Wits Vaccines and Infectious Diseases Analytics (Wits VIDA) Research Unit at the University of the Witwatersrand (Wits) have played a leading role [...]
-
Sugar restriction during the first 1,000 days after conception may significantly reduce a person’s risk of developing Alzheimer’s by up to 46%. Those are the [...]
-
A cell therapy called deramiocel could slow muscle weakening in boys and young men with advanced Duchenne muscular dystrophy (DMD) and may also slow heart [...]
